Antonio Gonzalez-Bahena
Mexico City, DIF, Mexico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12.
Journal: Frontiers in genetics
Published: January 27, 2022
Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention.
Journal: Bosnian journal of basic medical sciences
Published: January 20, 2022
Recommendations on the pharmacological treatment of epithelial ovarian cancer in Mexico.
Journal: Gaceta medica de Mexico
Published: January 03, 2022
Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
Journal: Cancer biomarkers : section A of Disease markers
Published: May 31, 2021
Validation of the QLQ-EN24 instrument for the assessment of health-related quality of life for women with endometrial cancer in México.
Journal: Archives of gynecology and obstetrics
Published: March 20, 2020
Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer.
Journal: Archives of medical research
Published: March 14, 2020
PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
Journal: Chinese clinical oncology
Published: February 08, 2020
Experiencia con el uso de olaparib en pacientes con cáncer de ovario.
Journal: Gaceta medica de Mexico
Published: December 03, 2019
Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients.
Journal: Translational oncology
Published: September 12, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026